Abstract
Introduction
Heat shock proteins (HSPs), also called stress proteins, are highly conserved proteins whose expression is induced by different kinds of stresses [1] . HSPs 
Main HSPs
Small HSPs are a group of proteins that vary in size from 15 to 30 kD and share sequence homologies and biochemical properties such as phosphorylation and oligomerization. HSP27, probably the most studied member of this family, is an ATP-independent chaperone whose main function is protection against protein aggregation [2] . HSP27 can form oligomers up to 1000 kD. The HSP27 dimer might be the building block for the multimeric complexes. HSP27 oligomerization is a dynamic process that depends on the phosphorylation status of the protein and exposure to stress [3] . Human HSP27 can be phosphorylated at three serine residues and its dephosphorylation enhances oligomerization. This phosphorylation is a reversible process catalysed by the MAPKAP kinases 2 
and 3 in response to a variety of stresses including differentiating agents, mitogens, inflammatory cytokines such as tumour necrosis factor-␣ (TNF-␣) and interleukin-1␤ (IL-1␤), hydrogen peroxide and other oxidants. HSP27 is expressed in many cell types and tissues, at specific stages of development and differentiation [3]. It is a late inducible HSP that accumulates in the cells after several different stresses such as oxidative stress, serum deprivation, anticancer drugs or radiation. In cancer cells, the basal expression of HSP27 is abnormally high and associates with cell resistance to anticancer therapy.
Mammalian HSP60, also called chaperonin, is mostly contained within the mitochondrial matrix, although it can also be detected in extra-mitochondrial sites including the cytosol [4, 5] . HSP60 is a constitutively expressed HSP, although its expression can slightly increase after certain stresses, mainly heat [6] . HSP60 [58] (Fig. 1B) .
HSP90 regulates the activity and stability of many transcription factors and kinases implicated in apoptosis such as NF-B, p53, Akt, Raf-1 and JNK [59] . [60] . HSP90 associates to mutated p53 and stabilizes the protein. [61] . On the other hand, p53 could repress HSP90␣ gene expression in UV irradiated cells [62] . Other transcription factors whose function could be modulated by HSP90 include Her2 and HIF1␣ [63, 64] . [65] and in B-lymphocytes [66] [69] (Fig. 1A) . [70] . This HSP70 function depends on both its chaperone and its ATP hydrolytic domains [71] (Fig. 1A) .
HSP90 can affect NF-B survival activity via the IKK complex, which is composed of two catalytic and one regulatory subunits (Fig. 1B). HSP90 and Cdc37 are also present, association mediated through the kinase domain of the catalytic subunits

In chronic leukaemia cells, inhibition of HSP90 by geldanamycin down-regulates mutated p53 protein while up-regulating wild-type p53
HSP90 interacts with and stabilizes phosphorylated Akt (Fig. 1A). In turn, phosphorylated Akt can phosphorylate the pro-apoptotic Bcl-2 family protein Bad and the caspase-9 [37], leading to their inactivation and to cell survival. Akt has also been shown to phosphorylate the I-B kinase, which results in promotion of NF-B-mediated cell survival [35]. HSP90 also interacts with Raf-1 and the dissociation of this complex results in apoptosis in mast cells
HSP70, coupled to HSP40, blocks Bax translocation preventing mitochondrial outer membrane permeabilization and thereby inhibiting the release of cytochrome c and that of other mitochondrial apoptogenic molecules such as apoptosis inducing factor (AIF)
Cytosolic HSP60 could form a complex with the pro-apoptotic protein Bax [72] . [73 , 74] . In neuroblastoma cells, mitochondrial HSP60 has been shown to protect mitochondrial normal oxidative phosphorylation functions by selectively acting at the complex IV activity level, thereby preserving ATP generation and decreasing cytochrome c release [75] (Fig. 1A) .
In [78] (Fig. 1A) .
HSPs' targets at the post-mitochondrial level
We, and other groups, have demonstrated that HSP27 can prevent the activation of caspases by directly sequestering cytochrome c when released from the mitochondria into the cytosol [79, 80] (Fig.  1A) [81] . HSP27 can also increase the anti-oxidant defence of cells by decreasing ROS cell content [82] and neutralizes the toxic effects of oxidized proteins [83] . This latter effect may occur more specifically in neuronal cells and involves phosphorylated HSP27 [84] . HSP27 may also affect membrane blebs formation, one of the morphological changes that take place on the late phase of apoptosis. The actin-myosin system has been proposed as a source of contractile force for bleb formation [85] and HSP27 is a cap-binding protein that plays a role in F-actin reorganization [86] (Fig. 1A) .
Li et al. [87] found HSP70-inhibited apoptosis downstream of the release of cytochrome c and upstream of the activation of caspase-3. Indeed, HSP70 has been demonstrated to directly bind to Apaf-1, thereby preventing the recruitment of procaspase-9 to the apoptosome [88] . The ATPase domain of HSP70 was described to be necessary for this interaction [89] . [92] (Fig. 1A) [94] (Fig. 1A) .
A release from the mitochondria (Fig. 1) [95, 96] (Fig. 1A) .
HSPs and the extrinsic death receptor pathway
HSP27 inhibits Fas-induced apoptosis [97] . The phosphorylated form of HSP27 directly interacts with Daxx. This latter protein connects Fas signalling to the protein kinase Ask1 that mediates a caspaseindependent cell death [98] (Fig. 1B) . [99] . HSP70 can block the cleavage of Bid by activated caspase-8 [99] . [100, 101] . [102] . The role of HSP70 in Fas-mediated apoptsis is more controversial with opposite effects that depend on the cell context [103, 104] (Fig. 1B) . [106] . Finally, in NIH3T3 fibroblasts, HSP90 has been shown to suppress TNF-␣-induced apoptosis by directly associating to Bid, thereby preventing its cleavage [107] (Fig. 1B) . [108] . [110] . This protective effect of HSP70 might be physiologically relevant as AIF sequestration by HSP70 reduces neonatal hypoxic/ischaemic brain injury [111] . In addition, HSP70 inhibits erythroblast apoptotis by blocking AIF nuclear import [112] . HSP70 associates also with EndoG to prevent DNA fragmentation [113] , but this association could involve AIF as a molecular bridge (Fig. 1B) .
HSP70 inhibits TNF-␣-induced cell death and this protective effect is lost in Bid homozygous-deleted mouse embryonic fibroblast (MEF) cells
Exposure of haematopoietic cells to TNF-␣ induces the activity of the pro-apoptotic doublestranded RNA-dependent protein kinase (PKR). An inhibitor of PKR is the Fanconi anaemia complementation group C gene product (FANCC). HSP70 interacts with the FANCC protein via its ATPase domain and, together with HSP40, inhibits TNF-induced apoptosis through the ternary complex HSP70, FANCC and PKR
In human chronic myeloid leukaemia (CML) cells, HSP70 can mediate Bcr-Abl-induced resistance to TNF␣-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by preventing the formation of DISCss involving DR4 and DR5
A key regulator in apoptosis induced by TRAIL is FLIP. It has been shown in glioma cells that HSP90␣ associates with FLIP(S) in a manner dependent on the ATP-binding NH2-terminal domain of the chaperone. Following TRAIL exposure, HSP90␣ and its client protein FLIP(S) are recruited to the DISC. HSP90␣ depletion blocked the recruitment of FLIP(S) to the DISC and thereby sensitized resistant glioma cells to TRAIL-induced apoptosis [105]. HSP90 has also been shown to interact with and stabilize the Receptor Interacting protein (RIP). Upon ligation of tumor necrosis factor receptor (TNFR)-1, receptor interacting protein (RIP)-1 is recruited to the receptor and promotes the activation of NF-B and JNK. Degradation of RIP-1 in the absence of HSP90 precludes activation of NF-B mediated by TNF-␣ and sensitizes cells to apoptosis
HSPs and alternatives, caspase-independent, apoptosis-like pathways
Upon activation of the intrinsic pathway not only cytochrome c is released from the mitochondria. AIF and endonuclease G (EndoG) are also released upon an apoptotic stimulus. These two mitochondria intermembrane proteins translocate to the nucleus and triggers caspase-independent nuclear changes
HSP70 has been shown to prevent cell death in conditions in which caspase activation does not occur, due to the addition of exogenous caspase inhibitors [109], or in cells in which Apaf-1 or caspase-9 were genetically inactivated [110], indicating that the cytochrome c/Apaf-1/caspase was not the sole pathway of the anti-apoptotic action of HSP70. Indeed, HSP70 directly binds to AIF and inhibits AIF-induced chromatin condensation. HSP70 neutralizes the apoptogenic effects of AIF in cell-free systems, in intact cells microinjected with recombinant HSP70 and/or AIF protein, as well as in cells transiently transfected with AIF cDNA. Of note, endogenous levels of HSP70 seem to be sufficiently high to control AIF-mediated apoptosis since down-regulation of HSP70 by an antisense construct sensitized the cells to serum withdrawal and AIF
Lysosomes also functions as integrators of cell death signals in many different cell death scenarios [114] . Lysosomal proteases, of which the most studied are the cathepsins, translocate from the lysosomal lumen to the cytosol in response to a wide variety of apoptotic stimuli, such as TNF-␣ [115, 116] , Fas [117] , microtubule stabilizing agents [118] , staurosporine [119] , p53 activation [120] , oxidative stress [117, 121] , growth factor deprivation [117] and lysosomotropic agents [121, 122] . Upon release to the cytosol, cathepsins can trigger mitochondrial outer membrane permeabilization [115, 119, 120, 122, 123] . Cathepsins release can also ensue an apoptotic morphology that is independent of the mitochondria release of cytochrome c or AIF [116, 124] . [125, 126] . Lysosomes positive for HSP70 display an increased size and resistance against chemical and physical membrane destabilization [125] (Fig. 1B) . [127] by a still unknown mechanism.
HSP70 is found in the endolysosomal membranes of many tumours and stressed cells where it inhibits the release of lysosomal cathepsins into the cytosol
HSP90␤ is involved in signalling prolactin-induced apoptosis during spermatogenesis. Prolactin receptor is a client protein of HSP90␤ and its inhibition promotes spermatogonial apoptosis
What directs the interaction of a HSP with a given apoptotic partner?
HSPs [128] . In contrast, the phosphorylated form of the protein directly interacts with Daxx [98] . These results suggest that the oligomerization/phosphorylation of the protein alters HSP27 conformation and hence determine its capacity to interact with different apoptotic proteins. The essential HSP27 anti-apoptotic function seems to take place in the cytosol [79] . Accordingly, leptomycin B, which is an inhibitor of the nuclear export of proteins, triggers nuclear accumulation of HSP27, which prevents its protective functions [129] .
In [136] . HSP60 can also be found in the plasma membrane where its expression correlates with increased apoptosis in adult cardiac myocytes [137] . These opposite HSP60 chaperone functions and/or its cellular localization could be regulated by the phosphorylation/dephosphorylation of the protein [5] . [138, 139] . In acute myeloid leukaemia cells, HSP27 prevents drug-induced apoptosis [140] . In multiple myeloma cells, down-regulation of HSP27 can restore the apoptotic response to dexamethasone through activation of the intrinsic, caspasedependent pathway [69] .
Role of HSPs in haematological malignancies
In contrast to normal, non-transformed, cells and tissues where the expression of stress-inducible
Importantly [141] . In HTLV1-associated adult T cell leukaemias, HSP90 inhibition abrogates cell cycle progression and induces apoptosis through inhibition of the NF-B pathway [142] . In malignant mast cells, 17-AAG inhibits the constitutive activity of the receptor tyrosine kinase c-kit and downstream signalling molecules Akt and STAT3 [143] . In acute myeloid leukaemia cell lines, 17-AAG reduces the level of the constitutively activated tyrosine kinase FLT-3 with internal tandem repeat mutation and downstream STAT5 activity [144] . [145, 146] .
HSP90 also functions as a chaperone for ZAP-70 (Zeta-associated of 70 kD), a protein that is abnormally expressed in patients with aggressive chronic lymphocytic leukaemia (CLL), and its inhibition leads to ZAP-70 degradation and leukaemic cell death
Recently, a novel HSP90 inhibitor, IPI-504, was tested in mice with Bcr-Abl leukaemias that resist to the tyrosine kinase inhibitor imatinib because of a T315I mutation in the fusion gene. The combination of IPI-405 and imatinib increases mice survival and appears to eliminate leukaemic stem cells [147] . A combination of 17-AAG and cytarabine also renders acute myeloid leukaemia cells more sensitive to death [148] . [159] [160] [161] .
Studies in Bcr-Abl human leukaemia cells suggest that HSP70 is also a promising therapeutic target for reversing drug resistance, probably due to its ability to inhibit death pathways both upstream and downstream of the mitochondrial signalling [102, 162] [28, 29, 168] . However, the structural complexity of this molecule makes difficult the search for therapeutic molecules that could neutralize it [3] .
Although the repercussions at the long term of HSPs inhibition deserves to be evaluated (for instance the genome stability for HSP90 [169] ) or the evolution of neuronal degenerative diseases for HSP27 [84, 170] 
